STOCK TITAN

Director Aktar Mert receives Kyverna (KYTX) RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kyverna Therapeutics director Aktar Mert reported equity awards consisting of restricted stock units and stock options. The filing shows a grant of 5,093 shares of Common Stock as restricted stock units that vest in full on the earlier of May 27, 2027, or immediately before the company’s 2027 annual stockholder meeting, if service continues through that date. Mert also received stock options covering 20,582 shares of Common Stock at an exercise price of $8.59 per share, which become fully vested and exercisable on the same timeline. Following the restricted stock grant, Mert holds 21,727 shares of Common Stock directly.

Positive

  • None.

Negative

  • None.
Insider Aktar Mert
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 20,582 $0.00 --
Grant/Award Common Stock 5,093 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 20,582 shares (Direct, null); Common Stock — 21,727 shares (Direct, null)
Footnotes (1)
  1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
RSU grant 5,093 shares Restricted stock unit award of Common Stock
Stock options granted 20,582 shares Options on Common Stock granted to director
Option exercise price $8.59 per share Conversion or exercise price for stock options
Option expiration May 27, 2036 Expiration date of stock options
Shares owned after grant 21,727 shares Total Common Stock directly held following RSU award
Underlying option shares 20,582 shares Common Stock underlying the stock option award
restricted stock unit financial
"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercisable financial
"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027..."
annual meeting of stockholders financial
"immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service..."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aktar Mert

(Last)(First)(Middle)
C/O KYVERNA THERAPEUTICS, INC.
5980 HORTON ST., STE 200

(Street)
EMERYVILLE CALIFORNIA 94608

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026A5,093(1)A$021,727D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$8.5905/27/2026A20,582 (2)05/27/2036Common Stock20,582$020,582D
Explanation of Responses:
1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
2. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
By: /s/ Samantha H. Eldredge, as Attorney-in-fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kyverna Therapeutics (KYTX) report for Aktar Mert?

Kyverna Therapeutics reported that director Aktar Mert received equity awards consisting of restricted stock units and stock options. These awards increase his direct ownership in the company and reflect standard director compensation rather than an open-market purchase or sale.

How many Kyverna Therapeutics (KYTX) shares did Aktar Mert receive as restricted stock units?

Aktar Mert received 5,093 shares of Kyverna Therapeutics Common Stock as a restricted stock unit award. These units convert into shares once they fully vest, aligning his compensation with long-term company performance and continued board service.

What stock options were granted to Aktar Mert by Kyverna Therapeutics (KYTX)?

Aktar Mert was granted stock options covering 20,582 shares of Kyverna Therapeutics Common Stock at an exercise price of $8.59. These options become fully vested and exercisable based on time and service conditions tied to the 2027 vesting schedule.

When do Aktar Mert’s Kyverna Therapeutics (KYTX) equity awards vest?

Both the restricted stock units and stock options vest in full on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual meeting of stockholders. Vesting is contingent on his continuous service to the company through the applicable date.

How many Kyverna Therapeutics (KYTX) shares does Aktar Mert own after this Form 4?

After the reported restricted stock unit grant, Aktar Mert directly owns 21,727 shares of Kyverna Therapeutics Common Stock. This figure excludes the additional 20,582 shares underlying the granted stock options, which are exercisable only after vesting conditions are met.

Is Aktar Mert’s Kyverna Therapeutics (KYTX) Form 4 a buy or a grant?

The Form 4 reflects grant or award acquisitions, not an open-market buy. Both the restricted stock units and stock options were awarded as compensation, with no purchase price paid for the awards themselves at the grant date.